Form 4: Revolution Medicines COO Margaret Horn Reports Acquisition of Shares and Stock Options

Margaret Horn, Chief Operating Officer of Revolution Medicines, reports the acquisition of 41,000 shares of common stock and 143,500 stock options.

Summary

• Margaret Horn, the Chief Operating Officer of Revolution Medicines, filed a Form 4 on March 5, 2024.
• The report details changes in her beneficial ownership of the company's securities.
• On March 1, 2024, Ms. Horn acquired 41,000 shares of common stock.
• She also acquired options to purchase 143,500 shares of common stock at an exercise price of $29.80.
• These options vest monthly over four years from March 1, 2024.
• Following these transactions, Ms. Horn beneficially owns 142,467 shares of common stock, including 100,013 restricted stock units, and 143,500 stock options.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document is a standard SEC filing reporting changes in beneficial ownership. The acquisition of shares and options by the COO could be seen as a slightly positive signal, but it's a routine occurrence.

Positives

• The acquisition of shares and stock options by a key executive could be interpreted as a positive sign of confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The transactions reported may have a minor impact on shareholder sentiment.

Key Dates